The UCSF Lethal Arrhythmia Database (LAD) is qualified by the US Food and Drug Administration (FDA) as part of the Medical Device Development Tool (MDDT) program. The LAD is designed to test and report the performance of algorithms to correctly detect episodes of asystole, ventricular fibrillation and ventricular tachycardia in patient data from bedside monitoring systems. The LAD is composed of continuous signals (e.g. ECG waveforms, SpO2, invasive arterial blood pressure and transthoracic impedance recordings), acquired in >5,000 Intensive Care Unit (ICU) patients over a period of 20 months. Of these data, 19 months are qualified by the MDDT program and the remaining month is held out separately for testing purposes.
The LAD is annotated for lethal cardiac arrhythmias by a team of experts in a systematic manner, specifically for ventricular fibrillation (VF), asystole (AS), and ventricular tachycardia (VT). The LAD-MDDT is considered a reference dataset to be used for external testing and therefore is not available for algorithm development or training.
Information about access procedures are described on the LAD FAQ page.
For more details about the LAD's development, please see the FDA documentation.
To begin the process to request LAD reference testing of a submitted algorithm, please contact us.